Global Mycoplasma Testing Market Size By Type (PCR, ELSA), By Application (Cell Line Testing, Virus Testing), By Region, And Segment Forecasts, 2023 to 2032

The Global Mycoplasma Testing Market was valued at USD 0.95 billion in 2023 and is projected to reach USD 2.02 billion by 2031, growing at a CAGR of 9.8% during the forecast period of 2023 to 2031. The market growth is primarily fueled by the rising demand for biologics and biosimilars, increasing R&D activities in the life sciences sector, and strict regulatory guidelines regarding contamination control in biopharmaceutical production. Mycoplasma contamination is a significant concern in cell culture-based manufacturing processes, making routine testing critical to ensure the safety, efficacy, and quality of final products.

Drivers:

Rising Adoption of Biopharmaceuticals:

The increasing use of monoclonal antibodies, vaccines, and gene therapies is creating a strong demand for mycoplasma testing. Biopharmaceutical manufacturers are investing in advanced quality control measures to meet stringent safety requirements.

Stringent Regulatory Standards:

Regulatory bodies like the FDA, EMA, and WHO have mandated comprehensive mycoplasma testing protocols in biologics production. These requirements are pushing companies to adopt reliable and validated mycoplasma detection systems.

Growing R&D in Cell Culture and Biotechnology:

As the use of cell lines in research, drug development, and diagnostics increases, mycoplasma testing becomes an integral step in ensuring data reliability and product quality, thereby driving market growth.

Restraints:

High Cost of Advanced Testing Methods:

The implementation of PCR-based and rapid testing kits often involves high setup costs, especially for small biotech firms and academic labs, which could limit broader adoption.

Lack of Technical Expertise in Developing Regions:

Limited availability of skilled personnel to perform molecular mycoplasma testing in emerging markets can hinder the growth of the market in these regions.

Opportunity:

Technological Advancements in Rapid Detection Kits:

Innovations in nucleic acid amplification techniques and automation in testing platforms are making mycoplasma detection faster and more sensitive, creating lucrative opportunities for diagnostics companies.

Expansion of CROs and CDMOs:

The growing number of contract research and manufacturing organizations focusing on biologics development is expected to boost demand for mycoplasma testing services, particularly in Asia-Pacific and Latin America.

Market by System Type Insights:

Among the system types, PCR-based mycoplasma testing kits dominated the market in 2023 due to their high sensitivity, specificity, and compliance with regulatory standards. PCR methods are widely adopted in pharmaceutical quality control for detecting even minute levels of contamination. However, enzymatic testing kits are gaining traction due to their cost-effectiveness and simplicity, especially in low-throughput labs.

Market by End-use Insights:

The Pharmaceutical & Biotechnology Companies segment held the largest market share in 2023. These entities conduct regular mycoplasma testing as part of stringent quality control protocols during biologics manufacturing. The Academic & Research Institutes segment is also expanding due to increased use of cell lines and primary cultures in fundamental research and clinical trials.

Market by Regional Insights:

North America emerged as the leading region in 2023, driven by a well-established biopharmaceutical industry, advanced healthcare infrastructure, and strong regulatory compliance. Asia-Pacific is forecasted to experience the highest CAGR, propelled by rising R&D expenditure, expanding biotech hubs in countries like China and India, and growing investment in CROs and CDMOs.

Competitive Scenario:

Key players in the Global Mycoplasma Testing Market include Thermo Fisher Scientific, Lonza Group, Charles River Laboratories, Merck KGaA, Promega Corporation, Roche Diagnostics, Sartorius AG, Bio-Rad Laboratories, American Type Culture Collection (ATCC), and Agilent Technologies. These companies are focusing on enhancing their product portfolios, entering strategic partnerships, and expanding into emerging markets to reinforce their positions.

Scope of Work – Global Mycoplasma Testing Market

Report Metric Details

Market Size (2023) USD 0.95 billion

Projected Market Size (2031) USD 2.02 billion

CAGR (2023-2031) 9.8%

Key Segments by System Type PCR-Based Kits, Enzymatic Kits, ELISA-Based Kits

Key Segments by End-Use Pharmaceutical & Biotechnology Companies, Academic & Research Institutes

Leading Region North America

Key Players Thermo Fisher Scientific, Lonza, Merck KGaA, Charles River, Bio-Rad

Growth Drivers Rising Biologics Production, Regulatory Requirements, R&D Expansion

Opportunities Rapid Detection Tech, Growth of CROs and CDMOs

Key Market Developments:

2023: Thermo Fisher Scientific launched a new ultra-sensitive PCR-based mycoplasma detection kit compatible with automated platforms to improve workflow efficiency in biologics production.

2023: Charles River Laboratories expanded its testing services with a new mycoplasma QC lab in Asia to cater to the rising demand from biopharmaceutical clients.

2024: Merck KGaA introduced a next-gen real-time PCR system integrated with cloud-based analytics for rapid and compliant mycoplasma testing.

FAQs:

What is the current market size of the Global Mycoplasma Testing Market?

The Global Mycoplasma Testing Market was valued at USD 0.95 billion in 2023.

What is the major growth driver of the Global Mycoplasma Testing Market?

The market is primarily driven by the increasing production of biologics and strict regulatory requirements for contamination testing.

Which is the largest region during the forecast period in the Global Mycoplasma Testing Market?

North America is expected to remain the largest region due to its advanced biopharma sector and robust regulatory framework.

Which segment accounted for the largest market share in Global Mycoplasma Testing Market?

The Pharmaceutical & Biotechnology Companies segment held the largest market share in 2023.

Who are the key market players in the Global Mycoplasma Testing Market?

Leading players include Thermo Fisher Scientific, Lonza, Charles River Laboratories, Merck KGaA, and Bio-Rad Laboratories.